SCHEMBL305259

SCHEMBL305259

Cc1nc(Cl)cc(NCCO)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.65
CYP2C19 P33261 1/20 0.65
GAA P10253 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 3/20 0.43
CYP1A2 P05177 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GLA P06280 1/20 0.41
CDC7 O00311 1/20 0.41
ROCK2 O75116 1/20 0.41
MAP4K4 O95819 1/20 0.41
PIM1 P11309 1/20 0.41
PRKACA P17612 1/20 0.41
CDK2 P24941 1/20 0.41
GSK3B P49841 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23299899 0.82 CYP2D6 (0.60) CYP2D6CYP2C19GAAMEN1KMT2A
SCHEMBL9217028 0.81 CYP2D6 (0.69) CYP2D6CYP2C19GAAMEN1KMT2A
SCHEMBL11981653 0.81 ALDH1A1 (0.56) CYP2D6CYP2C19GAAMEN1KMT2A
SCHEMBL16841139 0.80 GAA (0.46) CYP2D6CYP2C19GAAMEN1KMT2A
SCHEMBL9592998 0.79 GAA (0.46) CYP2D6CYP2C19GAAMEN1KMT2A
SCHEMBL11278078 0.79 CYP2D6 (0.61) CYP2D6CYP2C19GAAMEN1KMT2A
SCHEMBL6118631 0.79 CYP2D6 (0.51) CYP2D6CYP2C19GAAMEN1KMT2A
SCHEMBL8053292 0.79 CYP2D6 (1.00) CYP2D6CYP2C19GAAMEN1KMT2A
SCHEMBL3877330 0.78 CYP2D6 (0.59) CYP2D6CYP2C19GAAMEN1KMT2A
Hydrochloric Acid SCHEMBL8049480 0.77 CYP2D6 (0.97) CYP2D6CYP2C19GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors AMGEN INC. (US) 2012-06-28 US disclosed
US-8093238-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-01-10 US disclosed
EP-2398791-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS Amgen, Inc (US) 2011-12-28 EP disclosed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 WO disclosed
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-03-18 US disclosed
EP-2076512-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-07-08 EP disclosed
WO-2008044022-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-04-17 WO disclosed
US-4153695-A VIRICIDES ELI LILLY AND COMPANY (US) 1979-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165334-A1 Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors MTOR, PIKFYVE, RICTOR CYP2D6 2775/4885CYP2C19 1159/4885GAA 1461/4885
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors JAK1, MTOR, MOK CYP2D6 1308/4885CYP2C19 629/4885GAA 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.